A clinical trial of LM-101 injection
Latest Information Update: 13 Oct 2022
At a glance
- Drugs LM 101 (Primary)
- Indications Colorectal cancer; Non-Hodgkin's lymphoma; Renal cell carcinoma
- Focus Adverse reactions
Most Recent Events
- 13 Oct 2022 New trial record
- 05 Sep 2022 According to a LaNova Medicines Limited media release, the LM-101 for injection clinical trial application has been accepted by the China National Medical Products Administration (NMPA).